<DOC>
	<DOCNO>NCT01702155</DOCNO>
	<brief_summary>The purpose study determine safety efficacy DFP-10917 give via continuous 7 14 day infusion patient acute leukemia ( AML ALL ) .</brief_summary>
	<brief_title>Phase I/II Study DFP-10917 Patients With Acute Leukemia</brief_title>
	<detailed_description>This study determine safety efficacy DFP-10917 patient AML ALL . The Phase I dose-escalation portion study determine high tolerable dose regimen ( 7 14 day continuous infusion ) base safety data patient refractory relapse AML ALL . The phase II portion investigate safety efficacy DFP-10917 , dose regimen determine Phase I portion , patient refractory relapse AML .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>1 . Patients must pathologicallyconfirmed acute leukemia , refractory relapse standard therapy disease conventional systemic chemotherapy reliably effective effective therapy available Phase II Only : Patient must histologically pathologically confirm diagnosis AML base WHO classification refractory standard therapy , conventional systemic chemotherapy reliably effective , effective therapy available . Patients age 60 year old newly diagnose AML eligible , refuse , standard care also eligible . 2 . Aged â‰¥ 18 year . 3 . ECOG Performance Status 0 , 1 2 . 4 . Adequate clinical laboratory value ( i.e. , plasma creatinine &lt; = 1.5 x upper limit normal ( ULN ) institution , bilirubin &lt; =1.5 x ULN , alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; = 2.5 x ULN ) . 5 . Absence CNS involvement leukemia . 6 . Absence uncontrolled intercurrent illness , include uncontrolled infection , cardiac condition , organ dysfunction . 7 . Signed informed consent prior start study specific procedure . 8 . Women childbearing potential must negative serum urine pregnancy test . Male female patient must agree use acceptable contraceptive method duration study least one month last drug administration . 1 . The interval prior treatment time study drug administration &lt; 2 week cytotoxic agent &lt; 5 halflives noncytotoxic agent . Exceptions : Use hydroxyurea allow start study may administer day 5 first cycle . 2 . Any &gt; grade 1 persistent clinically significant toxicity prior chemotherapy . 3 . Extensive prior radiotherapy 30 % bone marrow reserve , prior bone marrow/stem cell transplantation . 4 . Any concomitant condition opinion investigator could compromise objective study patient 's compliance . 5 . A pregnant lactating woman . 6 . Current malignancy another type . Exceptions : Patients may participate previously treat currently control prostate cancer , adequately treat situ cervical cancer basal cell skin cancer malignancy evidence disease 2 year . 7 . Patient acute promyelocytic leukemia ( APL ) . 8 . Patients know HIV , HBV HCV infection ( note : testing infection require ) . 9 . Documented know clinically significant bleed disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>